DelveInsight’s “Treatment Resistant Depression Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of historical and forecasted epidemiology as well as Treatment-Resistant Depression therapeutics market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
To Know in detail about the Treatment-Resistant Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Treatment-Resistant Depression Market Forecast
Some of the key facts of the Treatment-Resistant Depression Market Report:
- In April 2026, COMPASS Pathways announced that the US FDA granted an NDA rolling review request and awarded a Commissioner’s National Priority Voucher (CNPV) for COMP360 (psilocybin) for the treatment of TRD, further accelerating its regulatory pathway toward potential approval.
- In March 2026, Atai Beckley announced that BPL-003 (mebufotenin benzoate nasal spray) demonstrated rapid and durable antidepressant effects in patients with TRD, with the company remaining on track to initiate its Phase III development program in Q2 2026.
- In January 2026, Johnson & Johnson presented new post-hoc Phase III analyses of SPRAVATO (esketamine) at the American College of Neuropsychopharmacology Annual Meeting, highlighting improvements in anhedonia among adults with TRD and reinforcing the therapy’s clinical utility in the treatment landscape.
- The total Treatment-Resistant Depression (TRD) Market Size in the 7MM was approximately ~USD 3,100 million in 2022 and is projected to increase during the forecast period (2026–2036).
- In 2022, the US captured the highest Treatment-Resistant Depression Market Share (84%), followed by Germany (5%), out of all the 7MM countries.
- The UK accounted for a market size of ~USD 110 million in 2022. The market size is further expected to increase during the forecast period.
- In Japan, the Treatment-Resistant Depression market size is expected to increase at a CAGR of 2% during the forecast period (2026–2036).
- As per DelveInsight analysis, there were approximately 6.6 million prevalent cases of TRD across the 7MM in 2025, and this figure is projected to rise by 2036.
- In 2025, an estimated 1.2 million males and 3.4 million females in the US were affected by TRD. The condition was more prevalent among females, reflecting broader trends in depression diagnoses.
- DelveInsight’s analysis indicates that in Japan, the highest number of TRD cases in 2025 occurred in the 40─49 age group, with more than 90,000 cases.
- In 2025, the UK reported around 120,000 male and 290,000 female cases of TRD, with this gender trend expected to rise by 2036.
- SPRAVATO was approved by FDA in 2019, and it is the only FDA-approved nasal spray indicated for Treatment-Resistant Depression.
- For MIJ821 (Novartis), expected to launch in the US in 2027, drug uptake is expected to be slow-medium, with a probability-adjusted peak patient share of ~1% in the US, expected to peak at 8 years from the year of launch.
- Key Treatment-Resistant Depression Companies: Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.
- Key Treatment-Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), BPL-003, NV-5138, VLS-01, and others.
Treatment-Resistant Depression Overview
Treatment-Resistant Depression typically refers to an inadequate response to at least two antidepressant medications used for a sufficient time at an adequate dose with adequate affirmation of treatment adherence. It is a relatively common occurrence in clinical practice, with up to 50–60% of patients not achieving adequate response following antidepressant treatment. The European Union’s Committee for Human Proprietary Medicinal Products (CHMP) defines it as a condition where consecutive treatments with two products of different classes, used for a sufficient time at an adequate dose, fail to induce an acceptable effect, though this broad definition does not properly specify what “sufficient time,” “adequate dose,” and “acceptable effect” mean. TRD is usually linked to higher rates of comorbidity, particularly with other psychiatric disorders, chronic pain, and fibromyalgia, and is associated with environmental factors such as lower socioeconomic status, non-supportive social environment, family conflicts, chronic stressors, multiple loss events, lower levels of education and social support, and work dysfunction. Management includes pharmacological strategies (switching, combining, and augmenting antidepressants such as SSRIs and tricyclic antidepressants) and nonpharmacological options such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and vagus nerve stimulation (VNS).
Get a Free sample for the Treatment-Resistant Depression Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market
Treatment-Resistant Depression Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036, using a patient-based model.
Treatment-Resistant Depression Epidemiology Segmentation: The Treatment-Resistant Depression market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
- Total Prevalent Cases of Treatment-Resistant Depression in the 7MM
- Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the 7MM
- Gender-specific Cases of Treatment-Resistant Depression in the 7MM
- Age-specific Cases of Treatment-Resistant Depression in the 7MM
Download the report to understand which factors are driving Treatment-Resistant Depression epidemiology trends @ Treatment-Resistant Depression Prevalence
Treatment-Resistant Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment-Resistant Depression market or expected to get launched during the study period. The analysis covers Treatment-Resistant Depression market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Treatment-Resistant Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in Phase III, Phase II, and Phase I stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Treatment-Resistant Depression Therapies and Key Companies
- SPRAVATO (esketamine): Johnson & Johnson
- MIJ821: Novartis
- COMP360 (Psilocybin): COMPASS Pathways
- BPL-003 (mebufotenin benzoate nasal spray): AtaiBeckley
- NV-5138: Navitor Pharmaceuticals
- VLS-01 (VLS-01-BU): AtaiBeckley
Discover more about therapies set to grab major Treatment-Resistant Depression market share @ Treatment Resistant Depression Treatment Drugs
Treatment-Resistant Depression Market Strengths
- The growing prevalence of Treatment-Resistant Depression, driven by rising diagnosis rates and mental health awareness, offers a stable and expanding market demand for advanced treatments.
- SPRAVATO’s approval and REMS-supported market presence, along with breakthrough and priority-review designations granted to pipeline candidates like COMP360, provide regulatory momentum and market visibility for TRD therapies.
Treatment-Resistant Depression Market Opportunities
- Expansion of psychedelic-based therapeutic development, including COMP360, BPL-003, and VLS-01, offers potential for rapid, durable antidepressant responses in patients who have failed conventional treatment approaches.
- Increasing focus on personalized, biomarker-guided treatment strategies and improving market access/reimbursement frameworks could reduce trial-and-error prescribing and support broader adoption of novel therapies.
Scope of the Treatment-Resistant Depression Market Report
- Study Period: 2022-2036
- Forecast Period: 2026-2036
- Coverage: 7MM
- Key Treatment-Resistant Depression Companies: Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others
- Key Treatment-Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), BPL-003, NV-5138, VLS-01, and others
- Treatment-Resistant Depression Therapeutic Assessment: Treatment-Resistant Depression current marketed and Treatment-Resistant Depression emerging therapies
- Treatment-Resistant Depression Market Dynamics: Treatment-Resistant Depression market drivers and Treatment-Resistant Depression market barriers
- Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis (efficacy via MADRS score, safety/tolerability, route and frequency of administration, order of entry and designation, probability of success, addressable patient pool)
- Treatment-Resistant Depression Unmet Needs, KOL’s views, Analyst’s views, Treatment-Resistant Depression Market Access and Reimbursement
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us
Kanishk
